Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 1 AL 15

The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer's Disease

de Lima IBQ, Ribeiro FM.

Curr Neuropharmacol. 2023;21(2):164-182. doi: 10.2174/1570159X20666211223140303.

The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease

Bland AR, Ashton JC, Kamal MA, Sahebkar A.

CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.

Impact of the Cannabinoid System in Alzheimer's Disease

Li S, Huang Y, Yu L, Ji X, Wu J.

Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.

Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease

Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.

Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.

Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease

Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.

CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease

Martins GL, Ferreira CN, Palotás A, Rocha NP, Reis HJ.

Curr Neuropharmacol. 2023;21(2):202-212. doi: 10.2174/1570159X20666220327215245.

Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease

Unnisa A, Greig NH, Kamal MA.

Curr Med Chem. 2023;30(3):255-270. doi: 10.2174/0929867329666220328125206.

Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review

Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.

CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.

Dopaminergic Signaling as a Plausible Modulator of Astrocytic Toll-Like Receptor 4: A Crosstalk between Neuroinflammation and Cognition

Gurram PC, Manandhar S, Satarker S, Mudgal J, Arora D, Nampoothiri M.

CNS Neurol Disord Drug Targets. 2023;22(4):539-557. doi: 10.2174/1871527321666220413090541.

The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease

Wang Y.

CNS Neurol Disord Drug Targets. 2023;22(4):577-598. doi: 10.2174/1871527321666220417005115.

Therapeutic Effects of Thymoquinone on Alzheimer's Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels

Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.

CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.

Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review

Grover S, Jain S.

Curr Rev Clin Exp Pharmacol. 2023;18(3):255-269. doi: 10.2174/2772432817666220425121323.

Berberine: Is it a Promising Agent for Mental Disorders Treatment?

Shayganfard M.

Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.

The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease

Ravikumar M, Mohan S, Velpandian C.

Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.

Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease

Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.

Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias